Effects of docetaxel combined with radiotherapy on immune function, tumor marker indices, and suppression of gene inactivation in breast cancer patients

This study aimed to investigate the clinical efficacy of combining docetaxel with radiotherapy in breast cancer patients who have undergone surgery. 110 breast cancer patients admitted to our hospital were selected between January 2023 and June 2023 and randomly allocated into two groups (n = 55/group) using a randomized numerical table method. After surgery, the control group received docetaxel, while the study group received docetaxel in conjunction with X-ray intensity-modulated radiation therapy. Their clinical effectiveness, tumor markers, DNA methyltransferase (DNMT1), oncogene cripto-1 (CP-1), and CUE structural domain protein 2 (CUEDC2) expression levels and adverse events were compared before and after treatment. After treatment, we found no significant differences in T lymphocyte subpopulation indices between the two groups (p > 0.05), while the study group had significantly lower levels of all tumor markers, including DNMT1, CP-1 and CUEDC2, compared to the control group (p < 0.05). The incidence of adverse events in the study group (9.09%) was slightly higher than in the control group (5.45%), but the difference was not statistically significant (p > 0.05). In summary, postoperative docetaxel combined with X-ray intensity-modulated radiotherapy may lower tumor marker levels, inhibit malignant tumor cell behavior, enhance overall clinical efficacy, and extend patient survival without significantly impacting immune function or increasing the risks of adverse effects.

Docetaxel; Radiotherapy; Breast cancer patients; Immune function; Tumor markers; Inhibiting gene inactivation

[1] Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, et al. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cellular and Molecular Life Sciences. 2022; 79: 539.

[2] Köksal M, Hoppe C, Schröder A, Scafa D, Koch D, Sarria GR, et al. Decision regret in breast cancer patients after adjuvant radiotherapy. The Breast. 2023; 68: 133–141.

[3] Dane B, Doshi A, Gfytopoulos S, Bhattacharji P, Recht M, Moore W. Automated radiology-pathology module correlation using a novel report matching algorithm by organ system. Academic Radiology. 2018; 25: 673–680.

[4] Warth B, Palermo A, Rattray NJW, Lee NV, Zhu Z, Hoang LT, et al. Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells. Metabolites. 2019; 9: 7.

[5] Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Jukkola A, Tanner M, Ahlgren J, et al. Adjuvant capecitabine for early breast cancer: 15-year overall survival results from a randomized trial. Journal of Clinical Oncology. 2022; 40: 1051–1058.

[6] Dover L, Dulaney C. Prostate stereotactic body radiation therapy margins, accelerated partial breast irradiation techniques, total neoadjuvant therapy local control, hyperfractionated reirradiation, hyaluronic acid rectal spacer, and concurrent docetaxel for head and neck cancer. Practical Radiation Oncology. 2023; 13: 267–272.

[7] Yan M, Yuan P, Ouyang Q, Cheng Y, Han G, Wang D, et al. A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer. Therapeutic Advances in Medical Oncologyd. 2022; 24: 17588359221122715.

[8] Ben Dhia S, Loap P, Loirat D, Vincent-Salomon A, Cao K, Escalup L, et al. Concurrent radiation therapy and dual HER2 blockade in breast cancer: assessment of toxicity. Cancer Radiother. 2021; 25: 424–431. (In French)

[9] Wang Y, Huang J, Wu Q, Zhang J, Ma Z, Ma S, et al. Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38. Investigational New Drugs. 2021; 39: 458–468.

[10] El Bakraoui K, El Morabit B. Orbital metastasis from triple-negative breast cancer: case report and literature review. Case Reports in Oncology. 2020; 13: 1042–1046.

[11] Luo Y, Ye Y, Chen Y, Zhang C, Sun Y, Wang C, et al. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer. Frontiers in Immunology. 2023; 14: 1140993.

[12] Trokic D, Marosevic G, Simeunovic V, Lekic S, Babic B, Gojkovic Z. High Ki67 as negative predictor for response to concurrent radiotherapy plus Capecitabine in chemo-resistant advanced breast cancer. Journal of B.U.ON. 2021; 26: 466–474.

[13] Wang X, Cong Y, Qiao G, Zhang S, Wang L. Primary breast cancer patient with poliomyelitis: a case report. World Journal of Clinical Cases. 2020; 8: 6190–6196.

[14] Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, et al. A case of breast cancer during pregnancy treated with neoadjuvant chemotherapy during pregnancy. Japanese Journal of Cancer and Chemotherapy. 2022; 49: 289–292. (In Japanese)

[15] Zhang X, Zhang Z, Cao M, Liu B, Mori M, Luoh S, et al. A randomized parallel controlled phase II trial of recombinant human endostatin added to neoadjuvant chemotherapy for stage III breast cancer. Clinical Breast Cancer. 2020; 20: 291–299.e3.

[16] Dos Santos RLB, Osorio-de-Castro CGS, Sobreira-da-Silva MJ, Pepe VLE. First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil. Frontiers in Pharmacology. 2023; 14: 1069505.

[17] Yamamuro M, Konishi J, Nozaki Y, Ueno M, Ishida T, Kamo N, et al. A case of lung metastasis of the breast cancer with a remarkable response to stereotactic body radiation therapy (SBRT). Japanese Journal of Cancer and Chemotherapy. 2020; 47: 1878–1880. (In Japanese)

[18] Srivastava N, Usmani SS, Subbarayan R, Saini R, Pandey PK. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Frontiers in Oncology. 2023; 13: 1199105.